Pharming Group (PHGUF)
(Delayed Data from OTC)
$0.91 USD
-0.04 (-4.72%)
Updated Apr 25, 2024 09:30 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PHGUF 0.91 -0.04(-4.72%)
Will PHGUF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PHGUF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHGUF
Pharming Group NV (PHGUF) to Report Q3 Results: What Awaits?
PHGUF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PHGUF
Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion
Pharming Group’s Strong Performance and Growth Prospects Justify Buy Rating
Pharming Group price target raised by EUR 0.10 at RBC Capital
Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript
Pharming Group’s Strong Financial Performance and Growth Potential Merit Buy Rating